stockrow
Saturday 7 November 2026
Export SILO’s income statement to Excel — free account
Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +73.3%
- Free cash flow
- +39.2%
Quarter to June 2026, against a year earlier
1.33
0.04
+3.10%
Follow SILO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | — | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | +4.2% | 1 | — | — | +1,237.8% | |
| Gross margin, % | 100.00 | — | 0.00 | 32.51 | — | 92.99 | 91.96 | 91.96 | 91.96 | 38.56 | 11.81 | (61.4) pt | ||||||
| EBT | (1) | 0 | (1) | (1) | (3) | 4 | (4) | (4) | (4) | (4) | (4) | +16.0% | ||||||
| EBT margin, % | (2,234.94) | 0.00 | 0.00 | (2,495.81) | 0.00 | 5,865.36 | (5,419.42) | (5,036.20) | (6,092.79) | (5,863.66) | 0.00 | (3,628.7) pt | ||||||
| Net income | (1) | 0 | (1) | (1) | (3) | 4 | (4) | (4) | (4) | (4) | (4) | +16.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.56 | 0.47 | 0.35 | 0.29 | 0.13 | 0.00 | n/m | |||||
| Earnings | — | 0.11 | (0.30) | (0.65) | (0.69) | 19.76 | (25.65) | (17.99) | (17.84) | (7.50) | (5.34) | n/m | ||||||
| Cash flow | 0.00 | (0.09) | 0.08 | (0.51) | (0.26) | (17.99) | (22.95) | (15.70) | (15.62) | (8.34) | (3.04) | n/m | ||||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.03) | (0.53) | n/m | ||||||
| Free cash flow | 0.00 | (0.09) | 0.08 | (0.51) | (0.26) | (17.99) | (22.95) | (15.70) | (15.62) | (9.37) | (3.57) | n/m | ||||||
| Book value | 0.00 | 0.36 | 0.12 | (0.01) | 0.29 | 71.58 | 67.85 | 30.07 | 20.51 | 11.28 | 4.45 | n/m | ||||||
| Shares, m | — | 3 | 3 | 2 | 4 | 0 | 0 | 0 | 0 | 1 | 1 | (20.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | 0.00 | — | 3.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.5 | |||||
| P/S | 0.00 | — | — | 0.00 | — | 190.02 | 97.47 | 65.04 | 45.52 | 39.60 | 20.28 | 62.5 | ||||||
| P/B | 0.00 | — | — | 0.00 | — | 1.49 | 0.68 | 0.76 | 0.65 | 0.45 | 0.30 | 0.6 | ||||||
| EV/Sales | 0.00 | — | — | 0.00 | — | 46.01 | (60.40) | (41.37) | (52.77) | (55.61) | (52.27) | (23.4) | ||||||
| EV/FCF | 0.00 | — | — | (517.26) | — | (1.44) | 1.24 | 0.92 | 0.99 | 0.86 | 0.96 | (73.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | 0 | (1) | (1) | (2) | (3) | (3) | (4) | (5) | (3) | +47.2% | |||||
| Capex | — | — | — | — | — | — | — | — | — | (1) | (1) | — | ||||||
| Free cash flow | 0 | 0 | 0 | (1) | (1) | (2) | (3) | (3) | (4) | (5) | (4) | +49.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | 2 | 1 | 0 | 1 | 10 | 11 | 7 | 5 | 7 | 5 | +20.6% | |||||
| Net debt | (1) | (2) | (1) | 0 | (1) | (10) | (11) | (8) | (7) | (7) | (5) | +21.2% | ||||||
| Shareholders’ equity | 1 | 1 | 0 | 0 | 1 | 9 | 10 | 6 | 5 | 6 | 5 | +25.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (171.28) | 24.24 | (77.66) | (150.21) | (323.51) | 41.95 | (35.32) | (38.17) | (57.96) | (56.31) | (70.96) | +115.0 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (880.40) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 0.00 | 34.79 | (120.40) | (527.07) | (493.96) | 48.34 | (40.29) | (44.81) | (78.37) | (74.56) | (91.23) | (74.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | — | +14.7% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
Silo Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HCWB HCW Biologics Inc. | $2.3M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| APVO Aptevo Therapeutics Inc. | $2.3M | — (loss-making) | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLXN Silexion Therapeutics Corp | $2.2M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | Compare |
| BRTX Biorestorative Therapies, Inc. | $2.1M | — (loss-making) | — (loss-making) | −7.20% (below 0%: shrinking) | n/m | −35.26% (below 0%: shrinking) | 68.10% | (14,593.53%) | Compare |
| SILO Silo Pharma, Inc. | $2.1M | — (loss-making) | 18.4× | 0.00% | n/m | +39.17% (above 0%: growing) | (15.00%) | 0.00% | |
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.0M | — (loss-making) | — (loss-making) | — | n/m | −62.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $2.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENLV Enlivex Ltd. | $2.0M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDVA Splash Beverage Group, Inc. | $1.9M | — (loss-making) | — (loss-making) | −99.57% (below 0%: shrinking) | n/m | −95.72% (below 0%: shrinking) | 42.86% | 0.00% | Compare |
| Median of peers | $2.1M | — | — | +10.71% | — | −28.05% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 30 June 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 521.75k | 498.54k | 1.60 |
| 2024 | 630.05k | 630.05k | 6.19 |
| 2023 | 569.01k | 569.01k | 6.79 |
Ownership
Directors and executive officers, together
3.63%
Many Ads, Inc.
12.40%
Intracoastal Capital, LLC
9.99%
SEG Opportunity Fund LLC
5.33%
Anson Investments Master Fund LP
5.33%
Anson East Master Fund LP
5.33%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement